Healthcare · NSE: ZYDUSLIFE · BSE: 532321
Zydus Lifesciences: how the business works
Zydus Lifesciences makes generic medicines for the US and branded medicines for India, and earned ₹27,148 crore of revenue in FY26.
Follow Zydus Lifesciences
Email me when Zydus Lifesciences's page is updated after results.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
Zydus Lifesciences Limited · Ahmedabad, Gujarat · Founded 1995
Updated for Q2 FY27 · checked
- Revenue, FY26
- ₹27,148 cr
- Profit to shareholders, FY26 (restated)
- ₹5,095 cr
- Manufacturing facilities
- 44
- Employees (group, approx.)
- 30,000
- Promoter holding, 30 Sep 2026
- 75.01%
The short version
Zydus Lifesciences in 5 points
1 · What it sells
Zydus Lifesciences makes generic medicines for the US, branded medicines for India, consumer health products and orthopaedic implants, and its FY26 revenue from operations was ₹27,148 crore.
2 · Who pays it
In FY26, buyers in the US paid 43.2% of Zydus's revenue, buyers in India 35.8%, Europe 9.9% and other countries 11.2%.
3 · What it keeps from ₹100
Of every ₹100 that came in during FY26, Zydus kept ₹18.4 as profit after ₹1.9 of one-off charges and with ₹4.6 of currency gains counted against costs, and its profit before one-off items, joint-venture share and tax was ₹7,203 crore.
4 · Where the operating profit comes from
Pharmaceuticals earned ₹7,049 crore of segment profit before one-off items and tax in FY26, consumer products ₹267 crore, and medical technologies lost ₹113 crore.
5 · The one thing to watch
Net debt (Cityfort calculation) went from net cash of ₹4,643 crore on 31 Mar 2025 to ₹8,034 crore on 30 Sep 2026, and the company put its net debt at 0.62 times EBITDA on its own measure.
Sources: From Zydus Lifesciences' FY26 annual report, its Q2 FY27 results and press release, and its 4 Nov 2026 earnings call · checked
01Where the money goes · FY26
Where does ₹100 of Zydus Lifesciences' money go?
Zydus Lifesciences · FY26
Receipt for every ₹100
| Materials and goods bought | ₹26.4 |
|---|---|
| Employees | ₹16.0 |
| Other running costs (after currency gains) | ₹25.2 |
| Depreciation and amortisation | ₹4.9 |
| One-off charges | ₹1.9 |
| Interest, tax and minority owners' share, less joint-venture profit | ₹7.3 |
| Kept as profit for shareholders | ₹18.4 |
| Total | ₹100 |
Each line = amount ÷ total money in × 100. Lines may not add to exactly ₹100 because of rounding.
How this is worked out
Of every ₹100 that came in (revenue ₹27,148 crore + other income ₹510 crore), from the money flow above; each line ÷ ₹27,658 crore × 100 (Cityfort calculation).
Save this receipt as an image
Embed this receipt or the key numbers
Paste this code into a blog or website to show the card you choose, with a link back to this page.
Each week: the next company due to report results, explained in 5 points.
We'll email you once a week with what changed on Cityfort. Facts only, no tips. Unsubscribe any time.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
02The business in one line
What does Zydus Lifesciences do?
Wholesalers, distributors and hospitals in the US, India and other countries pay Zydus for its medicines and health products; most of the money goes on materials, staff and running costs such as research, and ₹18.4 of every ₹100 was left as profit in FY26.
- In FY26 buyers in the US paid 43.2% of Zydus's revenue and buyers in India 35.8%; one customer, not named, paid 12.4%.
- Of every ₹100 that came in during FY26, ₹26.4 went on materials, ₹16.0 on staff and ₹25.2 on other running costs, after currency gains.
03Who pays it
Who pays Zydus Lifesciences?
Buyers in the US
43.2%
of revenue
Generic and specialty medicines. One US-based wholesaler owed more than 10% of Zydus's trade receivables on 31 Mar 2026. Share is of FY26 revenue by customer location.
Buyers in India
35.8%
of revenue
Branded medicines reach patients through a distributor network and chemists, and hospitals buy directly. India also buys Zydus Wellness consumer products.
Buyers in Europe
9.9%
of revenue
Rose from ₹402 crore in FY25 to ₹2,675 crore in FY26, the first year with Amplitude (France) and Comfort Click (UK) in the accounts.
Buyers in other countries
11.2%
of revenue
Medicines sold in other markets through subsidiaries and distributors.
- Buyers in the US43.2%
- Buyers in India35.8%
- Buyers in Europe9.9%
- Buyers in other countries11.2%
Customer concentration
One customer, not named, paid ₹3,364 crore, 12.4% of FY26 revenue (Cityfort calculation from the segment note). A single customer also passed 10% in FY23 (13.3%) and FY24 (11.2%), but not in FY22 or FY25.
- Largest customer
- 12%
04How it makes money
How does Zydus Lifesciences make money?
Medicines cost little in materials; prices, new launches and approved plants shape the profit.
Materials cost ₹26.9 per ₹100 of revenue in FY26, down from ₹36.7 in FY22. Most costs are staff and other running costs, which include ₹2,273 crore of research. CRISIL's Dec 2024 report noted price erosion in US generics, and Zydus launched 5 new US products in Q2 FY27.
Materials cost per ₹100 of revenue
₹36.7₹26.9
FY22 to FY26
- Scientists develop generics and new drugs: R&D was ₹2,273 crore, 8.4% of FY26 revenue.
- Zydus files for approval: 4 US generic applications and 12 approvals in Q2 FY27.
- 44 plants make the medicines; US sales need plants that pass USFDA inspections.
- US wholesalers, India's distributors and hospitals buy them; doctors prescribe the India brands.
- US generic prices erode over time (CRISIL, Dec 2024), and new launches add sales: 5 in Q2 FY27.
- Cash from sales pays for more research and for purchases such as Assertio.
↺ Step 6 feeds back into step 1.
05Business segments · FY26
Which businesses make up Zydus Lifesciences?
Pharmaceuticals
82.6%Medicines and drug ingredients worldwide: US generics and specialty drugs, India brands, other countries and APIs. Profit shown is the segment result before one-off items and tax; the three segment results add up to ₹7,203 crore.
Revenue ₹22,412 cr · Operating profit ₹7,049 cr
Consumer products
14.6%Zydus Wellness (57.59% owned), including Comfort Click of the UK from 29 Aug 2025.
Revenue ₹3,954 cr · Operating profit ₹267 cr
Medical technologies
2.9%Amplitude Surgical's implants, a new segment from FY26 (loss restated to ₹113 crore from ₹178 crore). Earlier years had two segments, so the history shows only FY25 and FY26 on the three-segment basis.
Revenue ₹782 cr · Operating profit −₹113 cr
How the mix changed
- Pharmaceuticals
- Consumer products
- Medical technologies
Revenue by segment, FY25 to FY26.
₹ crore
See the numbers
06The numbers · Consolidated · ₹ crore
How has Zydus Lifesciences done?
Revenue
₹27,148 crFY26
Revenue rose every year, from ₹15,110 crore in FY22 to ₹27,148 crore in FY26, and Q2 FY27 revenue of ₹7,910 crore was 29.2% higher than in Q2 FY26.
₹ crore
See the numbers
Net profit
₹5,095 crFY26
Profit to shareholders rose from ₹1,960 crore in FY23, a year with ₹604 crore of one-off charges, to ₹5,095 crore in FY26 (restated), while FY22's ₹4,487 crore included ₹2,246 crore from the animal-health business sold in 2021. In the quarters, Q4 FY25 and Q4 FY26 carry one-off charges of ₹220 crore and ₹398 crore, Q2 FY26 and Q1 FY27 are restated, and Q3 and Q4 FY26 are as first filed; restated figures for them were not published.
₹ crore
See the numbers
Net profit for every ₹100 of revenue
₹18.8FY26
Zydus kept ₹18.8 to ₹19.7 of profit per ₹100 of revenue from FY24 to FY26, against ₹11.4 in FY23 and ₹29.7 in FY22, the year of the animal-health sale. The table's EBITDA margin is a Cityfort calculation on reported profit before tax: 29.7% in FY26, which includes ₹1,280 crore of currency gains and is after ₹517 crore of one-off charges. In Q2 FY27 it was 24.3%, against the company's own EBITDA margin of 24.0%.
Net margin: ₹ of net profit per ₹100 of revenue
See the numbers
Free cash flow
−₹555 crFY26
Cash from operations fell from ₹6,781 crore in FY25 to ₹2,117 crore in FY26, with a ₹2,624 crore working-capital outflow and a ₹1,753 crore currency adjustment. Capital spending rose to ₹2,672 crore, so free cash flow was −₹555 crore, before ₹6,602 crore spent on acquisitions.
₹ crore · cash from operations minus spending on plants and equipment
See the numbers
See all yearly numbers
EBITDA = profit before interest, tax and wear-and-tear of assets. Financial year runs April to March (March year end). Net profit is the share belonging to the company's owners.
Sources (9)
07Who runs it
Who runs Zydus Lifesciences, and did they deliver?
Pankaj R. Patel
Chairman
Promoter; son of founder Ramanbhai Patel, per CRISIL.
Dr Sharvil P. Patel
Managing Director
Third-generation promoter, per CRISIL.
Ganesh N. Nayak
Director
Board member.
Tushar D. Shroff
Chief Financial Officer · since 2025
From 1 Sep 2025, after Nitin Parekh.
Dhaval N. Soni
Company Secretary
What they said, and what happened
1 delivered · 3 too early to tell
Said on 10 Feb 2026
Management said on the Q3 FY26 call that Zydus would still reach an EBITDA margin above 23% in Q4 FY26, even with very little or no lenalidomide sales.
DeliveredWhat happened
The company's own EBITDA margin was 33.7% in Q4 FY26, including ₹645 crore of currency gains; Cityfort's calculation on reported profit before tax gives 28.4%.
Said on 19 May 2026
Dr Sharvil Patel said on the Q4 FY26 call that Zydus expected "high teens growth" in FY27 consolidated revenue; on 11 Aug 2026 he said it would deliver strong double-digit growth for the year.
Too early to tellWhat happened
H1 FY27 revenue was ₹15,927 crore, 25.4% more than in H1 FY26.
Said on 19 May 2026
Dr Sharvil Patel said on the same call that the FY27 EBITDA margin was expected to be above 24%; on 4 Nov 2026 he said Zydus was on track for a 24% plus margin.
Too early to tellWhat happened
The company's own EBITDA margin was 24.0% in H1 FY27; Cityfort's calculation on reported profit before tax gives 24.3%.
Said on 19 May 2026
Management said on 19 May 2026 that FY27 capital spending would be around ₹1,500 crore, with quarterly depreciation around ₹550 crore.
Too early to tellWhat happened
Organic capital spending was ₹1,053 crore in H1 FY27, and depreciation was ₹605 crore in Q2 FY27.
Sources (11)
- Integrated Annual Report 2025-26 (FY26)
- CRISIL Ratings rating rationale, Zydus Lifesciences Ltd, 27 Dec 2024
- Change in CFO: Nitin Parekh to Tushar Shroff (from 1 Sep 2025)
- Q3 FY26 earnings call transcript (call 10 Feb 2026)
- Press release: financial performance for Q4 and full year FY26
- Q4 FY26 and FY26 audited results
- Q4 FY26 earnings call transcript (call 19 May 2026)
- Q1 FY27 earnings call transcript (call 11 Aug 2026)
- Q2 FY27 results (standalone and consolidated, with notes and balance sheet)
- Press release: financial performance for Q2 and H1 FY27
- Q2 FY27 earnings call transcript (call 4 Nov 2026)
08What could go wrong
What could go wrong for Zydus Lifesciences?
- Pricing
US generic prices and competition
US buyers paid 43.2% of FY26 revenue. CRISIL's Dec 2024 report notes price erosion in US generics. When giving the FY27 margin outlook on 19 May 2026, Dr Sharvil Patel cited competition for lenalidomide and mirabegron and saroglitazar launch costs.
Watch North America formulation sales each quarter: ₹3,315 crore in Q2 FY27.
- Regulation
USFDA plant inspections
The Baddi plant received a USFDA warning letter on 3 Jun 2026. The Jarod injectables plant received one in Aug 2024, which the FY26 annual report says was resolved. US sales depend on plants passing these inspections.
Watch Baddi remediation, and follow-up on the SEZ-II and Moraiya inspections, which closed with 1 and 5 observations.
- Debt
Debt after acquisitions
Net debt (Cityfort calculation) went from net cash of ₹4,643 crore on 31 Mar 2025 to ₹8,034 crore on 30 Sep 2026. The company put net debt at 0.62 times EBITDA on its own measure on 30 Sep 2026. CRISIL reaffirmed AAA/Stable on 10 Sep 2026.
Watch Net debt to EBITDA. Dr Sharvil Patel said on 4 Nov 2026 that Zydus is comfortable up to one times.
- Execution
Loss-making medical devices business
The medical technologies segment lost ₹113 crore in FY26 (restated) and ₹150 crore in H1 FY27, before one-off items and tax. Goodwill and other intangible assets rose from ₹7,092 crore on 31 Mar 2025 to ₹15,822 crore on 30 Sep 2026.
Watch The medical technologies segment result each quarter.
- Cash and liquidity
Weaker cash from operations in FY26
Cash from operations fell from ₹6,781 crore in FY25 to ₹2,117 crore in FY26, with a ₹2,624 crore working-capital outflow and a ₹1,753 crore currency adjustment on consolidation. Free cash flow was −₹555 crore.
Watch FY27 cash from operations. Inventories were ₹6,882 crore on 30 Sep 2026, up from ₹5,628 crore on 31 Mar 2026.
- Legal
US lawsuits and settlements
In US generic-drug pricing antitrust cases, plaintiffs alleged that many drug makers, including Zydus's US subsidiary, engaged in anti-competitive behaviour; it agreed on 5 Sep 2026 to pay US$5.9 million to indirect reseller plaintiffs, without any admission of fault or wrongdoing. In Feb 2026 Zydus agreed to pay Astellas US$120 million to end mirabegron patent litigation.
Watch New settlements or provisions in the results notes.
- Concentration
One large customer
One customer, not named, paid ₹3,364 crore, 12.4% of FY26 revenue. One US-based wholesaler owed more than 10% of trade receivables on 31 Mar 2026.
Watch The large-customer line in the FY27 segment note.
Sources (11)
- Integrated Annual Report 2025-26 (FY26)
- CRISIL Ratings rating rationale, Zydus Lifesciences Ltd, 27 Dec 2024
- Q4 FY26 earnings call transcript (call 19 May 2026)
- Press release: financial performance for Q2 and H1 FY27
- Receipt of USFDA warning letter for the Baddi formulations facility
- Clarification on receipt of USFDA warning letter for the Jarod injectables facility (intimation of 30 Aug 2024)
- Q2 FY27 results (standalone and consolidated, with notes and balance sheet)
- Intimation of credit rating: CRISIL letters dated 10 Sep 2026 (AAA/Stable, A1+ reaffirmed); rationale attached as scanned images
- Q2 FY27 earnings call transcript (call 4 Nov 2026)
- Settlement with indirect reseller plaintiffs, US generic drug pricing antitrust litigation (US$5.9 mn)
- Settlement agreement with Astellas on Myrbetriq (mirabegron)
09Supporters and critics
What do supporters and critics point to?
What supporters point to
- Revenue rose every year from FY22 to FY26, to ₹27,148 crore, and H1 FY27 revenue was 25.4% higher than in H1 FY26.
- India formulation sales rose 18.3% in Q2 FY27 to ₹1,884 crore, and international markets rose 33.2%.
- Zydus says it was the third-largest generics company in the US by prescriptions (IQVIA, 12 months to Mar 2026).
- Dr Sharvil Patel said branded products were about 57% of revenue in Q2 FY27, up 150 basis points from Q1.
- CRISIL reaffirmed its AAA/Stable rating on 10 Sep 2026.
What critics point to
- Q2 FY27 profit to shareholders was ₹926 crore, 26.6% less than in Q2 FY26, and the company's own EBITDA margin fell from 32.9% to 24.0%.
- Net debt (Cityfort calculation) was ₹8,034 crore on 30 Sep 2026, against net cash of ₹4,643 crore on 31 Mar 2025.
- Free cash flow was −₹555 crore in FY26, before ₹6,602 crore spent on acquisitions.
- The medical technologies segment lost ₹150 crore in H1 FY27.
- The USFDA issued a warning letter for the Baddi plant on 3 Jun 2026.
10What to watch next
What should you watch next at Zydus Lifesciences?
Next event
Q3 FY27 results
Date not announced yet.
US FDA date for saroglitazar
The US FDA set 27 Nov 2026 as its target action date for Zydus's saroglitazar application in PBC, a liver disease (announced 27 May 2026). Dr Sharvil Patel said on 4 Nov 2026 that FY28 would bring no meaningful revenue from it.
Plant inspections
Progress on the Baddi warning letter of 3 Jun 2026, and on the 1 and 5 USFDA observations at the SEZ-II and Moraiya plants.
Debt and margins
Net debt was 0.62 times EBITDA on 30 Sep 2026 on the company's own measure. Dr Sharvil Patel said on 19 May and 4 Nov 2026 that Zydus expects an FY27 EBITDA margin above 24%; H1 FY27 was 24.0% on the company's measure.
11Key facts
Key facts about Zydus Lifesciences
- What does Zydus Lifesciences do?
- Zydus Lifesciences, based in Ahmedabad, makes generic medicines for the US, branded medicines prescribed by doctors in India and medicines for other countries. It also sells consumer health products through Zydus Wellness and orthopaedic implants through Amplitude Surgical of France.
- How does Zydus Lifesciences make money?
- Zydus Lifesciences earns most of its money selling medicines. Of its ₹26,720 crore of product sales in FY26, North America formulations were ₹11,682 crore, India formulations ₹6,574 crore, consumer wellness ₹3,913 crore and international markets ₹3,070 crore.
- Who pays Zydus Lifesciences?
- In FY26 buyers in the US paid 43.2% of Zydus Lifesciences' ₹27,148 crore revenue, buyers in India 35.8%, Europe 9.9% and other countries 11.2%. One customer, not named, paid 12.4% of FY26 revenue.
- How big is Zydus Lifesciences?
- Zydus Lifesciences reported FY26 revenue of ₹27,148 crore and profit to shareholders of ₹5,095 crore (as restated in its Q2 FY27 results). It has 44 manufacturing facilities and about 30,000 employees.
- Who owns Zydus Lifesciences?
- On 30 Sep 2026 the promoter group owned 75.01% of Zydus Lifesciences, Indian institutions 11.28%, foreign investors 7.05% and others 6.66%. The FY25 annual report shows most promoter shares held by Pankaj R. Patel as trustee of the Zydus Family Trust.
- How much debt does Zydus Lifesciences have?
- On 30 Sep 2026 Zydus Lifesciences had borrowings of ₹13,250 crore and cash and liquid investments of ₹5,216 crore, a net debt of ₹8,034 crore (Cityfort calculation). On 31 Mar 2025 it had ₹4,643 crore more cash than debt.
- What has Zydus Lifesciences bought since 2025?
- Zydus Lifesciences bought French orthopaedic-implant maker Amplitude Surgical for a total cost of €300 million (Jul–Oct 2025) and US company Assertio for about US$166.4 million (Jun 2026). Its subsidiary Zydus Wellness bought Comfort Click of the UK for £239 million in Aug 2025.
- How did Zydus Lifesciences do in Q2 FY27?
- In Q2 FY27 (Jul–Sep 2026) Zydus Lifesciences' revenue rose 29.2% from a year earlier to ₹7,910 crore, while profit to shareholders fell 26.6% to ₹926 crore.
- What is Zydus Lifesciences' credit rating?
- CRISIL rated Zydus Lifesciences' long-term bank facilities AAA with a Stable outlook and its short-term debt A1+, reaffirmed in letters dated 10 Sep 2026.
Sources (10)
- Integrated Annual Report 2025-26 (FY26)
- Press release: financial performance for Q4 and full year FY26
- Q2 FY27 results (standalone and consolidated, with notes and balance sheet)
- Shareholding pattern as of 30 Sep 2026
- Annual Report 2024-25 (FY25)
- Completion of block acquisition of 85.6% of Amplitude Surgical
- Update on acquisition of Amplitude shares (tender offer and squeeze-out)
- Completion of acquisition and merger of Assertio Holdings Inc.
- Press release: financial performance for Q2 and H1 FY27
- Intimation of credit rating: CRISIL letters dated 10 Sep 2026 (AAA/Stable, A1+ reaffirmed); rationale attached as scanned images
Terms on this page
- Capital expenditure (capex)
- Credit rating
- Customer concentration
- Dividend payout ratio
- EBITDA
- FII and DII holding
- Free cash flow
- Market capitalisation
- Net debt
- Net profit
Each explains the term in plain English, with the same number from other companies on Cityfort.
Go deeper
More detail from the same filings. Open any section.
12What it sells
12What it sells
What does Zydus Lifesciences sell?
North America formulations
Generic and specialty medicines sold in the US and Canada. ₹11,682 crore of sales in FY26, 43.7% of product sales. Since Jun 2026 this includes Assertio's cancer-care biologic Rolvedon.
India formulations
Branded medicines prescribed by doctors in India. ₹6,574 crore in FY26. Medicines for long-term (chronic and sub-chronic) conditions were 56.9% of the portfolio in the 12 months to Sep 2026 (AWACS).
Consumer wellness
Zydus Wellness brands such as Glucon-D, Complan, Sugar Free, Nycil and Everyuth, plus UK online brands of Comfort Click from Aug 2025. ₹3,913 crore in FY26.
International markets formulations
Medicines sold in other countries through subsidiaries and distributors. ₹3,070 crore in FY26.
MedTech
Knee and hip implants from Amplitude Surgical, France, part of Zydus since 29 Jul 2025. ₹782 crore in FY26.
APIs and alliances
Active pharmaceutical ingredients (the chemicals inside medicines) sold to other drug makers, plus partner income. ₹698 crore in FY26.
What it does
- Does: Makes generic copies of off-patent medicines for the US market
- Does: Sells its own medicine brands to doctors and chemists in India
- Does: Develops its own new drugs, such as saroglitazar and desidustat
- Does: Sells consumer health and food products through Zydus Wellness
- Does: Makes knee and hip implants (prostheses) through Amplitude Surgical
What it does not do
- Does not: Does not earn most of its revenue in India: US buyers paid 43.2% of FY26 revenue, India 35.8%
- Does not: Does not own all of Zydus Wellness: it held 57.59% on 31 Mar 2026
- Does not: Does not report profit by country: profit is shown only for its three business segments
Sources (5)
13How the money flows
13How the money flows · FY26
How does money flow through Zydus Lifesciences?
Money in
- Revenue from operations₹27,148 cr
- Other income₹510 cr
The company
Zydus Lifesciences
₹27,658 cr came in
Money out
- Materials and goods bought₹7,293 cr
- Employees₹4,418 cr
- Other running costs (after ₹1,280 cr of currency gains)₹6,963 cr
- Depreciation and amortisation₹1,343 cr
- One-off charges (mostly the Astellas settlement)₹517 cr
- Interest, tax and minority owners' share, less joint-venture profit₹2,030 cr
- Profit to Zydus shareholders₹5,095 cr
- In FY26 Zydus took in ₹27,148 crore from sales plus ₹510 crore of other income.
- Materials and goods bought cost ₹7,293 crore, ₹26.4 of every ₹100 that came in.
- Staff cost ₹4,418 crore. Other running costs were ₹6,963 crore after ₹1,280 crore of currency gains (₹4.6 per ₹100) counted against them.
- One-off charges took ₹517 crore (₹1.9 per ₹100), ₹398 crore of it the Astellas patent settlement.
- After depreciation, interest, tax and the share of minority owners, ₹5,095 crore was left for Zydus shareholders.
14What it needs to run
14What it needs to run
What does Zydus Lifesciences need to run?
Plants
44 manufacturing facilities in FY26: 38 in India and 6 abroad. Plants selling to the US must pass USFDA inspections.
Research
10 R&D centres and over 1,500 scientists. R&D spending was ₹2,273 crore in FY26, 8.4% of revenue.
Product approvals
Each US generic needs an approved application (ANDA). In Q2 FY27 Zydus filed 4 and received 12 approvals, 2 of them tentative.
People
29,980 permanent employees on 31 Mar 2026, and about 30,000 people in all.
15Where it sells
15Where it sells · FY26
Where does Zydus Lifesciences sell?
- United States43.2%
- India35.8%
- Other countries11.2%
- Europe9.9%
Sources (1)
16Competitors and what protects it
16Competitors and what protects it
Who does Zydus Lifesciences compete with?
Sun Pharma
NSE: SUNPHARMA
Sells branded medicines in India and generic and specialty medicines in the US: India formulations ₹19,290 crore and US formulations ₹16,824 crore in FY26, per its results release.
Cipla
NSE: CIPLA
Sells branded medicines in India and generics in North America: One India ₹12,680 crore and North America ₹6,871 crore in FY26, per its results release.
Dr. Reddy's Laboratories
NSE: DRREDDY
Sells generics in North America and medicines in India: North America generics ₹11,374 crore and India ₹6,219 crore in FY26 (IFRS), per its results filing.
What protects the business
Each strength is scored 1 (weak) to 5 (strong) for the business, with the reason. It is not a rating of the share.
- US generics reach4 of 5
Zydus says it was the third-largest generics company in the US by prescriptions (IQVIA, 12 months to Mar 2026). North America formulation sales were ₹11,682 crore in FY26.
- India brands3 of 5
India formulation sales were ₹6,574 crore in FY26, against ₹19,290 crore for Sun Pharma and ₹12,680 crore for Cipla's One India business. Long-term-condition medicines were 56.9% of Zydus's India portfolio (AWACS, Sep 2026).
- Research and own drugs3 of 5
R&D was ₹2,273 crore, 8.4% of FY26 revenue, across 10 R&D centres. Its own new drugs include saroglitazar and desidustat.
- Plants and approvals3 of 5
44 manufacturing facilities. On 31 Mar 2026 none of its plants was under a warning letter, but the Baddi plant received one on 3 Jun 2026.
Weak spot
Reliance on US generics
US buyers paid 43.2% of FY26 revenue. CRISIL's Dec 2024 report noted price erosion in US generics, and management said in Feb 2026 it expected very little or no lenalidomide sales in Q4 FY26.
Sources (9)
- Press release: Sun Pharma reports Q4FY26 and FY26 results (peer filing)
- Press release: Q4 FY26 and FY26 results (peer filing)
- Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (peer filing)
- Integrated Annual Report 2025-26 (FY26)
- Press release: financial performance for Q4 and full year FY26
- Press release: financial performance for Q2 and H1 FY27
- Receipt of USFDA warning letter for the Baddi formulations facility
- CRISIL Ratings rating rationale, Zydus Lifesciences Ltd, 27 Dec 2024
- Q3 FY26 earnings call transcript (call 10 Feb 2026)
17Where growth could come from
17Where growth could come from
Where could Zydus Lifesciences' growth come from?
Managing Director Dr Sharvil Patel said on the Q4 FY26 call (19 May 2026) that Zydus expected "high teens growth" in FY27 consolidated revenue and an EBITDA margin above 24%. On 11 Aug 2026 he said it would deliver "strong double-digit growth" for the year, and on 4 Nov 2026 that it was on track for a 24% plus EBITDA margin.
Branded medicines in India
WorkingIndia formulations +18.3%, Q2 FY27
India formulation sales rose from ₹1,593 crore in Q2 FY26 to ₹1,884 crore in Q2 FY27, 24% of revenue. Branded sales grew 19%, the company said.
Status: Working, on track against what the company said.
International markets
Working+33.2%, Q2 FY27
International markets formulation sales were ₹1,001 crore in Q2 FY27, up from ₹751 crore a year earlier, and ₹3,070 crore in FY26.
Status: Working, on track against what the company said.
Consumer wellness
Working+76.1%, Q2 FY27
Sales were ₹1,122 crore in Q2 FY27, including Comfort Click (UK) from Aug 2025. The India business grew 29%, and the international business 12% on a like-for-like basis.
Status: Working, on track against what the company said.
US specialty medicines
New16% of US sales, Q2 FY27
Zydus completed its purchase of Assertio, whose products include the cancer-care biologic Rolvedon, on 16 Jun 2026 for about US$166.4 million. The company said branded sales were 16% of its US business in Q2 FY27.
Status: New, recently announced.
Saroglitazar in the US
NewFDA target date 27 Nov 2026
The US FDA gave priority review to Zydus's application for saroglitazar, its own drug, in PBC, a liver disease, with a target action date of 27 Nov 2026. Dr Sharvil Patel said on 4 Nov 2026: "FY28 will not be any meaningful revenue."
Status: New, recently announced.
Medical devices
EarlySegment loss ₹150 cr, H1 FY27
Medical technologies revenue was ₹509 crore in H1 FY27, and the segment lost ₹150 crore before one-off items and tax.
Status: Early, too early to judge.
Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.
Sources (8)
- Q4 FY26 earnings call transcript (call 19 May 2026)
- Q1 FY27 earnings call transcript (call 11 Aug 2026)
- Q2 FY27 earnings call transcript (call 4 Nov 2026)
- Press release: financial performance for Q2 and H1 FY27
- Press release: financial performance for Q4 and full year FY26
- Q2 FY27 results (standalone and consolidated, with notes and balance sheet)
- Completion of acquisition and merger of Assertio Holdings Inc.
- Update: US FDA Priority Review for saroglitazar NDA in PBC, PDUFA date 27 Nov 2026
18Financial strength and debt
18Financial strength · 30 Sep 2026
How much debt does Zydus Lifesciences have?
- Total debt₹13,250 cr
- Cash and investments₹5,216 cr
- Net debt (debt minus cash)₹8,034 cr
- Net worth (shareholders' money)₹27,817 cr
- Debt to equity
- 0.48×
- ₹ of debt for every ₹1 of shareholders' money
- Borrowings exclude lease liabilities (rent owed under leases) of ₹717 crore.
- Cash and liquid investments = cash ₹669 crore + other bank balances ₹883 crore + current investments ₹3,664 crore. Non-current investments of ₹3,452 crore are not counted. Net debt is a Cityfort calculation.
- Zydus's own measure, on a definition it does not disclose: net debt 0.19 times equity and 0.62 times EBITDA on 30 Sep 2026. Dr Sharvil Patel said on 4 Nov 2026 that net debt fell from ₹5,900 crore to ₹5,200 crore in the quarter.
- Net debt (Cityfort calculation) was ₹4,577 crore on 31 Mar 2026. In FY26 Zydus took ₹7,071 crore of new long-term borrowings and spent ₹6,602 crore on acquisitions.
- Goodwill and other intangible assets were ₹15,822 crore on 30 Sep 2026, against ₹7,092 crore on 31 Mar 2025 (Cityfort calculation: sum of the two lines).
- Net worth is the equity belonging to Zydus shareholders. Minority owners, mainly of Zydus Wellness, held another ₹2,506 crore.
19Who owns it
19Who owns it · Q2 FY27
Who owns Zydus Lifesciences?
- Promoters (founders or parent company)75.0%
- Foreign institutions (FII)7.1%
- Indian institutions (DII)11.3%
- Public and others6.7%
Promoter pledge
No promoter shares were pledged in Q2 FY27.
How ownership changed
* Pledged = share of the promoters' own holding reported as pledged. In older filings this can include shares “otherwise encumbered”; the governance flags say when.
Sources (13)
- Shareholding pattern as of 30 Sep 2026
- Shareholding pattern as of 30 Jun 2026
- Shareholding pattern as of 18 Jun 2026 (post-buyback, Reg 31(1)(c))
- Shareholding pattern as of 31 Mar 2026
- Shareholding pattern as of 31 Dec 2025 (revised)
- Shareholding pattern as of 30 Sep 2025
- Shareholding pattern as of 30 Jun 2025
- Shareholding pattern as of 31 Mar 2025
- Shareholding pattern as of 31 Dec 2024
- Shareholding pattern as of 30 Sep 2024
- Shareholding pattern as of 30 Jun 2024
- Shareholding pattern as of 31 Mar 2024
- Shareholding pattern as of 31 Dec 2023
20What it does with profit
20What it does with profit
What does Zydus Lifesciences do with its profit?
Dividend per share
₹1.00FY26
Dividend paid for each share, by financial year.
₹ per share
See the numbers
Buyback · 19 Jul 2022
Bought back 11,538,461 shares at ₹650 each (₹750 crore); the FY24 annual report says the shares were extinguished on 19 Jul 2022. The FY23 cash flow shows ₹863 crore paid including tax and costs.
₹750 cr
Buyback · 15 Mar 2024
Bought back 5,970,149 shares at ₹1,005 each (₹600 crore); the FY24 annual report says the shares were extinguished on 15 Mar 2024. The promoter's Zydus Family Trust received ₹387 crore.
₹600 cr
Buyback · 18 Jun 2026
Tender-offer buyback approved by the board on 19 May 2026: 8,730,158 shares (0.87%) bought at ₹1,260, raised from ₹1,150 on 27 May 2026, and extinguished on 18 Jun 2026. ₹1,106 crore paid including expenses; the promoter holding was 75.01% afterwards.
₹1,100 cr
21Governance signals
21Governance signals
What do Zydus Lifesciences' governance filings show?
- Auditor
- Deloitte Haskins & Sells LLP
- Auditor changes
- 4 Nov 2026: Deloitte Haskins & Sells LLP → Walker Chandiok & Co LLP (Mandatory rotation: Deloitte's second five-year term ends at the 32nd AGM, after the FY27 audit. The board approved Walker Chandiok from that AGM to the 37th AGM, subject to shareholder approval.)
- Audit qualifications
- None reported
- Related-party dealings
- This page does not summarise every related-party transaction. In FY24 Zydus paid ₹387 crore to the promoter's Zydus Family Trust for shares bought back from it, per the FY25 annual report. Zydus owned 57.59% of its subsidiary Zydus Wellness on 31 Mar 2026.
- Credit rating
- CRISIL AAA (long term), A1+ (short term) (outlook Stable), 10 Sep 2026
A credit rating describes the company's ability to repay debt. It is not a rating of the share.
Flags to know about
regulatory · 3 Jun 2026
USFDA warning letter for the Baddi plant
Received on 3 Jun 2026 after a records request under section 704(a)(4), not an on-site inspection. It references observations on the use of purified talc that did not meet current USP requirements. The company said it believes current operations and supplies from Baddi will not be affected.
other · 5 Sep 2026
US generic-drug pricing antitrust cases
Plaintiffs alleged that numerous drug makers, including Zydus Pharmaceuticals USA, engaged in anti-competitive behaviour. On 5 Sep 2026 the subsidiary agreed to pay US$5.9 million to settle with indirect reseller plaintiffs, without any admission of fault or wrongdoing.
disclosure · 4 Nov 2026
Earlier quarters restated
The Q2 FY27 results restated FY26, Q2 FY26 and Q1 FY27 after the Amplitude purchase-price allocation was finalised (FY26 profit to shareholders ₹5,040 crore → ₹5,095 crore). Restated Q3 and Q4 FY26 figures were not published.
pledge · 31 Dec 2025
Tiny promoter pledge in Dec 2025
A revised Dec 2025 shareholding filing shows 3,500 shares of one promoter-group member pledged, 0.0005% of the promoter holding. Filings from Mar 2026 show none.
Sources (10)
- Integrated Annual Report 2025-26 (FY26)
- Appointment of Walker Chandiok & Co LLP as statutory auditors (rotation, from the 32nd AGM)
- Annual Report 2024-25 (FY25)
- Intimation of credit rating: CRISIL letters dated 10 Sep 2026 (AAA/Stable, A1+ reaffirmed); rationale attached as scanned images
- Receipt of USFDA warning letter for the Baddi formulations facility
- Settlement with indirect reseller plaintiffs, US generic drug pricing antitrust litigation (US$5.9 mn)
- Q2 FY27 results (standalone and consolidated, with notes and balance sheet)
- Shareholding pattern as of 31 Dec 2025 (revised)
- Shareholding pattern as of 31 Mar 2026
- Shareholding pattern as of 30 Sep 2026
22What the market paid
22What the market paid · price as of 11 Nov 2026
What did the market pay for Zydus Lifesciences on 11 Nov 2026?
Price as of 11 Nov 2026 (shown for education; prices change daily).
Price as of 11 Nov 2026: ₹1,199.50, the NSE closing price. Market value = price × 997,503,832 shares = ₹119,651 crore. P/E shows how many rupees the market price is for each rupee of yearly profit per share: price ÷ ₹42.36 earnings per share of the last four quarters (H1 FY27 ₹18.84 + FY26 ₹50.63 − H1 FY26 ₹27.11, restated) = 28.3. P/B = market value ÷ shareholders' equity on 30 Sep 2026 (₹27,817 crore) = 4.3. Dividend yield = FY26 dividend of ₹1 ÷ price = 0.08%. All are Cityfort calculations.
- Share price
- ₹1,199.50
- Market value (market cap)
- ₹119,651 cr
- P/E
- 28.3×
- P/B
- 4.3×
Source: NSE security-wise bhavcopy (sec_bhavdata_full), 11 Nov 2026: ZYDUSLIFE EQ close Rs 1,199.50; Shareholding pattern as of 30 Sep 2026; Q2 FY27 results (standalone and consolidated, with notes and balance sheet) and 1 more
23How it got here
23How it got here
How did Zydus Lifesciences get here?
1952
Milestone
Cadila Laboratories founded
Ramanbhai Patel and Indravadan Modi set up Cadila Laboratories, the business Zydus grew from.
1995
Business-model change
Cadila Healthcare formed in the split
Cadila Healthcare was incorporated in 1995 after Cadila Laboratories split. CRISIL says the Modi family's share moved to a new company and the division run by Pankaj Patel became Cadila Healthcare.
2021
Business-model change
Animal-health business sold
Sold its India-focused animal-health business in Jul 2021. FY22 profit included ₹2,246 crore from these discontinued operations.
2022
Milestone
Renamed Zydus Lifesciences
Cadila Healthcare became Zydus Lifesciences on 24 Feb 2022.
2024
Crisis
Warning letter for the Jarod plant
Zydus received a USFDA warning letter for the Jarod injectables plant on 30 Aug 2024. The FY26 annual report says it was resolved.
2025
Business-model change
Into medical devices with Amplitude
Bought 85.6% of Amplitude Surgical (France) on 29 Jul 2025 and the rest by Oct 2025, for €300 million in all. Medical technologies became a new segment.
2025
Milestone
Comfort Click bought
Zydus Wellness bought UK online wellness company Comfort Click on 29 Aug 2025 for £239 million plus a £2.64 million profit ticker.
2026
Milestone
US biologics plants and Astellas settlement
Bought Agenus's two California biologics plants for US$75 million upfront plus up to US$50 million later (15 Jan 2026). Signed a US$120 million settlement with Astellas on 10 Feb 2026 to end mirabegron patent litigation, disclosed on 12 Feb 2026.
2026
Business-model change
Assertio bought; Baddi warning letter
Completed the US$166.4 million purchase of US specialty company Assertio on 16 Jun 2026. The Baddi plant received a USFDA warning letter on 3 Jun 2026.
Sources (12)
- Integrated Annual Report 2025-26 (FY26)
- CRISIL Ratings rating rationale, Zydus Lifesciences Ltd, 27 Dec 2024
- Annual Report 2021-22 (FY22)
- Annual Report 2022-23 (FY23)
- Clarification on receipt of USFDA warning letter for the Jarod injectables facility (intimation of 30 Aug 2024)
- Completion of block acquisition of 85.6% of Amplitude Surgical
- Update on acquisition of Amplitude shares (tender offer and squeeze-out)
- Q2 FY27 results (standalone and consolidated, with notes and balance sheet)
- Closing of acquisition of Agenus biologics manufacturing facilities (US)
- Settlement agreement with Astellas on Myrbetriq (mirabegron)
- Completion of acquisition and merger of Assertio Holdings Inc.
- Receipt of USFDA warning letter for the Baddi formulations facility
24Sources and changes
Where every number on this page comes from
Sources (45 documents)
- S1Integrated Annual Report 2025-26 (FY26) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 30 Jun 2026
- S2Annual Report 2024-25 (FY25) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 3 Jul 2025
- S3Annual Report 2023-24 (FY24) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 12 Jul 2024
- S4Annual Report 2022-23 (FY23) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 18 May 2023
- S5Annual Report 2021-22 (FY22) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 15 Jul 2022
- S6Q2 FY27 results (standalone and consolidated, with notes and balance sheet) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 4 Nov 2026
- S8Q4 FY26 and FY26 audited results · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 19 May 2026
- S9Q3 FY26 results · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 9 Feb 2026
- S11Q1 FY26 results · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 12 Aug 2025
- S12Press release: financial performance for Q2 and H1 FY27 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 4 Nov 2026
- S14Press release: financial performance for Q4 and full year FY26 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 19 May 2026
- S21Q2 FY27 earnings call transcript (call 4 Nov 2026) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 7 Nov 2026
- S22Q1 FY27 earnings call transcript (call 11 Aug 2026) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 18 Aug 2026
- S23Q4 FY26 earnings call transcript (call 19 May 2026) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 24 May 2026
- S24Q3 FY26 earnings call transcript (call 10 Feb 2026) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 15 Feb 2026
- S25Shareholding pattern as of 31 Dec 2023 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 8 Jan 2024
- S26Shareholding pattern as of 31 Mar 2024 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 9 Apr 2024
- S27Shareholding pattern as of 30 Jun 2024 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 11 Jul 2024
- S28Shareholding pattern as of 30 Sep 2024 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 9 Oct 2024
- S29Shareholding pattern as of 31 Dec 2024 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 20 Jan 2025
- S30Shareholding pattern as of 31 Mar 2025 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 12 Apr 2025
- S31Shareholding pattern as of 30 Jun 2025 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 18 Jul 2025
- S32Shareholding pattern as of 30 Sep 2025 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 14 Oct 2025
- S33Shareholding pattern as of 31 Dec 2025 (revised) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 27 May 2026
- S34Shareholding pattern as of 31 Mar 2026 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 9 Apr 2026
- S35Shareholding pattern as of 18 Jun 2026 (post-buyback, Reg 31(1)(c)) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 24 Jun 2026
- S36Shareholding pattern as of 30 Jun 2026 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 11 Jul 2026
- S37Shareholding pattern as of 30 Sep 2026 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 7 Oct 2026
- S38Intimation of credit rating: CRISIL letters dated 10 Sep 2026 (AAA/Stable, A1+ reaffirmed); rationale attached as scanned images · Zydus Lifesciences Ltd (filed with NSE) · Tier 1: company or exchange filing · 11 Sep 2026
- S39CRISIL Ratings rating rationale, Zydus Lifesciences Ltd, 27 Dec 2024 · CRISIL Ratings Ltd · Tier 2: rating agency or regulator · 27 Dec 2024
- S40NSE security-wise bhavcopy (sec_bhavdata_full), 11 Nov 2026: ZYDUSLIFE EQ close Rs 1,199.50 · NSE (nsearchives.nseindia.com) · Tier 1: company or exchange filing · 11 Nov 2026
- S41Clarification on receipt of USFDA warning letter for the Jarod injectables facility (intimation of 30 Aug 2024) · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 3 Sep 2024
- S45Completion of block acquisition of 85.6% of Amplitude Surgical · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 29 Jul 2025
- S46Update on acquisition of Amplitude shares (tender offer and squeeze-out) · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 26 Oct 2025
- S47Closing of acquisition of Agenus biologics manufacturing facilities (US) · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 15 Jan 2026
- S48Settlement agreement with Astellas on Myrbetriq (mirabegron) · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 12 Feb 2026
- S50Update: US FDA Priority Review for saroglitazar NDA in PBC, PDUFA date 27 Nov 2026 · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 27 May 2026
- S51Receipt of USFDA warning letter for the Baddi formulations facility · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 3 Jun 2026
- S52Completion of acquisition and merger of Assertio Holdings Inc. · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 16 Jun 2026
- S53Settlement with indirect reseller plaintiffs, US generic drug pricing antitrust litigation (US$5.9 mn) · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 5 Sep 2026
- S55Appointment of Walker Chandiok & Co LLP as statutory auditors (rotation, from the 32nd AGM) · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 4 Nov 2026
- S56Change in CFO: Nitin Parekh to Tushar Shroff (from 1 Sep 2025) · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 20 May 2025
- S57Press release: Sun Pharma reports Q4FY26 and FY26 results (peer filing) · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 22 May 2026
- S58Press release: Q4 FY26 and FY26 results (peer filing) · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 13 May 2026
- S59Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (peer filing) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 12 May 2026
Changes to this page (v2 · 17 Nov 2026)
- v2 · 17 Nov 2026Reworded the margin caption so it names the company (no numbers changed). (editorial update, Q2 FY27)
- v1 · 12 Nov 2026First version. (first version)
Numbers come only from tier 1 and tier 2 sources. Read how we research.
Disclaimer
For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.
Read the full disclaimerHide the full disclaimer
Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.
All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management are reported as statements, with their date and source; they are not our forecasts.